Cas:885272-74-2 (2-p-tolyl-imidazo[1,2-a]pyridin-3-yl)-acetonitrile manufacturer & supplier

Chemical Name:(2-p-tolyl-imidazo[1,2-a]pyridin-3-yl)-acetonitrile

CAS.NO:885272-74-2

Synonyms:2-(2-(p-Tolyl)imidazo[1,2-a]pyridin-3-yl)acetonitrile

Molecular Formula:C₁₆H₁₃N₃

Molecular Weight:247.29500

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:41.09000

Exact Mass:247.11100

LogP:3.37578

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 2-(2-(p-Tolyl)imidazo[1,2-a]pyridin-3-yl)acetonitrile chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-(2-(p-Tolyl)imidazo[1,2-a]pyridin-3-yl)acetonitrile physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-(2-(p-Tolyl)imidazo[1,2-a]pyridin-3-yl)acetonitrile Use and application,2-(2-(p-Tolyl)imidazo[1,2-a]pyridin-3-yl)acetonitrile technical grade,usp/ep/jp grade.

Related News: The announcement comes on top of Recipharm’s move into Morocco, which was fueled by local pledges of $500 million. The new facility under construction and due for completion in 2023 will employ 300 and have a capacity of 300 million units annually. Benzene, 1-iodo-4-[(trans,trans)-4′-propyl[1,1′-bicyclohexyl]-4-yl] manufacturers Lonza’s Nansha site is fully integrated within the company’s global manufacturing network. Scientists and engineers based in Nansha focus on API development and manufacturing for customers around the globe. [4-(aminomethyl)oxan-4-yl]methanamine,cyclobutane-1,1-dicarboxylate,platinum(2+) suppliers As of June’s end, there have been 100 reported GBS cases among J&J recipients, most of whom were hospitalized and one person has died, CDC officials reported. Most cases were seen in older men within 13 days following the single-dose vaccine. Amyloid β-Protein (1-42) (mouse, rat) vendor & factory The announcement comes on top of Recipharm’s move into Morocco, which was fueled by local pledges of $500 million. The new facility under construction and due for completion in 2023 will employ 300 and have a capacity of 300 million units annually. ,The Plexxikon patents are for compounds that reduce cancer cell growth by blocking V600E mutated BRAF. Patents were filed as early as 2005.